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Little information is currently available regarding post-
treatment outcome of TCR-targeted PCR in skin and/
or peripheral blood in patients with Mycosis Fungoides
(MF) when a dominant gene rearrangement is present
at time of diagnosis.To address this matter, a study eval-
uating the correlations between post-treatment clinical,
histological, blood and skin PCR data was conducted in
MF patients. Twenty-seven MF patients with dominant
gene rearrangement in skin lesions at time of diagnosis
were selected. Peripheral blood samples were investi-
gated as well before treatment and post treatment
molecular data in skin and blood were compared with
clinical and histological outcome. A dominant gene
rearrangement was detected before treatment in blood
of 16/25 patients. The dominant gene rearrangement
disappeared from cutaneous lesions in 8/13 patients dis-
playing complete clinical and histological response
whereas skin PCR remained positive in all 10 patients
with histologically persistent disease. A dominant gene
rearrangement was still present in blood in 10/16
patients after treatment and blood data were not
correlated with skin molecular response. This study
con¢rms frequent detection of a dominant gene rear-
rangement in peripheral blood in MF patients and
shows that PCR may remain positive in lesional sites
even when skin lesions are successfully treated. Key
words: Mycosis Fungoides; post-treatment outcome;TCR gene
rearrangement. J Invest Dermatol 121:614 ^617, 2003
M
olecular biology methods using mainlyTcell re-
ceptor (TCR)-targeted ampli¢cation by poly-
merase chain reaction (PCR) currently allow
the detection of the presence of a dominant
gene rearrangement in cutaneous lesions, but
also in peripheral blood in a high proportion of patients with
cutaneous T cell lymphomas, even at the early patch or plaque
stages of the disease (Weiss et al, 1985; Weiss et al, 1989; Wood
et al, 1994; Bachelez et al, 1995; Bakels et al, 1992; Veelken et al,
1995; Dommann et al, 1996; Curco et al, 1997; Muche et al, 1997;
Fraser-Andrews et al, 2000). A positive PCR in peripheral blood
of patients with cutaneousTcell lymphomas, however, might not
be related to the presence of tumoral cells in all cases but rather to
the age of the patients (Delfau-Larue et al, 2000). Conversely, few
data are currently available regarding the evolution of PCR data
in skin lesions and peripheral blood after treatment. Also, the
possible correlations that can be established between clinical and
histologic results of the treatment on one hand, and the outcome
of PCR data in skin and/or peripheral blood on another hand
have been poorly studied (Andrews et al, 2001). Finally, the pre-
dictive value of post-treatment PCR data as regards to the overall
outcome of the disease has only been seldom investigated. Ac-
cordingly, we designed a prospective study investigating the
outcome of PCR data both in skin lesions and, if applicable, in
peripheral blood in patients treated for mycosis fungoides (MF)
and displaying a dominant gene rearrangement in skin lesions be-
fore treatment. Furthermore, the relationship between post-ther-
apy PCR status and therapeutic results evaluated on clinical and
histologic grounds was analyzed.
MATERIALS ANDMETHODS
Patients and samples Twenty-seven patients with MF were selected for
this study, all of them ful¢lling the following criteria: clinical cutaneous
lesions consistent with the diagnosis before treatment; typical histologic
features, including band-like subepidermal mononucleated in¢ltrate with
epidermotropism and occasional atypical cells with convoluted nuclei; large
predominance of CD4þ cells among the in¢ltrating lymphocytes;
dominant gene rearrangement in skin lesions as disclosed by the PCR-based
method described below. Patients with multiple clonal bands (oligoclonal
pattern) were excluded from the study in an e¡ort to suppress any confusing
factor in the subsequent interpretation of PCRdata.The mean age of patients
was 55.4 y old (ranging from 22.3 to 76.5) at the time of diagnosis and sex
ratio (M/F) was 2:1. These 27 patients were staged according to the usual
classi¢cation of MF as follows: seven Ia, 18 Ib, and two IIa. For all patients,
clinical, histologic, immunologic, and PCR data were obtained before and 6
to 12 wk after the end of the treatment if the latter was of limited duration or
at least 6 mo after the therapy was implemented in the case of a more
protracted, chronic treatment. The mean interval of time between
pretreatment and post-treatment evaluation was 8.3 mo (ranging from 5.2 to
14.4 mo). More precisely, treatment e⁄ciency was evaluated on clinical
(disappearance or persistence of initial lesions), histologic, and immunologic
(multiple biopsies performed on sites close to areas where a speci¢c in¢ltrate
was present before treatment, processed for histologic and imm-
unohistochemical study) grounds, whereas post-treatment PCR was
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performed both in peripheral blood and in cutaneous areas as close as possible
to sites where it was positive before treatment. The therapies consisted in
psoralenþultraviolet A therapy (10 patients), oral retinoids (two patients), or
both (four patients), weekly intramuscular injections of methotrexate (two
patients), total body electron beam therapy (three patients), or in topically
applied BCNU (six patients).
PCR ampli¢cation of TCR gene encoding TCR-c chain Genomic
DNA was extracted from peripheral blood and skin samples using the
QIAamp DNA Mini Kit (Qiagen, les Ulis France) for TCR analysis. Two
multiplex-PCR were performed using TCR-g V1 to V8, V9, V10, V11, and
£uorescent JgG1/JgG2 or £uorescent JgP1/JgP2 consensus primers allowing
identi¢cation of virtually almost all known Vg Jg combinations.
Ampli¢cation was performed using 250 ng of genomic DNA as template,
together with 6.25 pmol of each primer, 200 mM of each deoxy-
ribonucleoside triphosphate, 2.5 mM of MgCl2 and 0.625 U Taq polymerase
(AmpliTaq, Perkin Elmer, les Ulis France) in a total volume of 25 mL. PCR
ampli¢cations were performed using aTechne GeniusThermocycler (Techne,
Cambridge, UK) with the following conditions: denaturation at 941C during
5 min followed by two cycles of denaturation at 941C (30 s), annealing at
611C (30 s), extension at 721C (30 s), followed by two cycles of denaturation
at 941C (30 s), annealing at 601C (30 s), extension at 721C (30 s), followed by
26 cycles of denaturation at 941C (30 s), annealing at 591C (30 s), extension at
721C (30 s) and followed by ¢nal extension period of 10 min at 721C.
Sizing analysis of PCR products Electrophoresis was carried out in an
ABI 373A DNA sequencer (Applied Biosystems, Les Ulis, France) using a
0.2 mm thick 5% denaturating Long-Ranger gel with 10% urea.
Fluorescent PCR products (2.5 mL) were admixed with 0.5 mL of internal
lane standard (GENESCAN-500 ROX Applied Biosystems) and 2.5 mL of
formamide loading bu¡er, denatured at 961C for 2 min, immediately
cooled on ice for 5 min and then loaded on the gel. Sizing of peaks were
performed using the Genescan analysis 672 software (Applied Biosystems).
Ampli¢cation gave rise to two ranges of length: 160 to 200 bpwithV9,V10,
and V11 primers and 250 to 290 bp withV1 toV8 primers.
Statistics Owing to the small size of subsets, statistical tests using
nonparametric methods (Mann^Wilcoxon^Whitney tests) were used to
assess the signi¢cance of the relationship between clinical and histologic
response on one hand and PCR data outcome, either in skin or in blood,
on another hand and to compare the percentage of cases where PCR
products of di¡erent sizes were obtained from skin and peripheral blood
samples, according to the stage of the disease.
RESULTS
Clinical, histologic, immunologic, and PCR (both in skin and
blood) data were obtained for all patients before and after treat-
ment was implemented, except for two of them for peripheral
blood PCR.
Initial peripheral blood data Pretreatment analysis of
peripheral blood displayed a positive PCR in 16 of 25
investigated patients (64%) (four of six stage Ia, 10 of 17 stage Ib,
two of two stage IIa). In three cases, the sizes of the ampli¢ed
fragments were di¡erent in skin and blood samples as visualized
on comigration analysis (two stage Ib, one stage IIa). This
increased rate of PCR products size discordance between skin
and peripheral blood in stage Ib was statistically signi¢cant
when compared with stage Ia but the limited size of samples
actually precluded any de¢nite conclusion.
Post-treatment data Post-treatment clinical, histologic,
immunologic, and PCR data were interpretable for all
investigated patients (Table I). A complete (14 patients) or partial
(eight patients, among which three showed o50% improve-
ment) clinical response was obtained in 22 of 27 patients.
Multiple biopsies showed a consistent disappearance of the
cutaneous lymphocytic CD4þ in¢ltrate in 17 cases (13 and four
with complete and partial clinical response, respectively), whereas
three displayed a partial result (one with complete clinical
remission and two with partial clinical improvement).
Post-treatment PCRwas negative in skin lesions in only eight
patients (30%) (three stage Ia, four stage Ib, one stage IIa) all of
them in complete clinical and histologic remission cases.
Conversely, it was still positive with ampli¢ed fragments of
identical size in the remaining 19 patients, including ¢ve stage Ib
patients for whom a complete clinical and histologic remission
was obtained.
Peripheral blood PCR became negative in six of 16 cases
(37.5%) (two stage Ia, three stage Ib, one stage IIa), including
four patients with complete clinical and histologic responses,
whereas PCR remained positive in blood in 10 patients of
whom four achieved a complete clinical and histologic
remission (three stage Ib, one IIa). PCR was still positive in
cutaneous lesions in four of the six patients with negative post-
treatment PCR in blood (three stage Ib, one IIa), whereas it
remained positive in peripheral blood in spite of skin molecular
response in two of eight patients (one stage Ib, one stage IIa). One
patient with stage IIa disease and negative post-treatment PCR in
skin but persistent positive PCR in blood, along with a complete
clinical and histologic clearance of lesions, relapsed within 9 mo
after the remission was completed. He experienced reappearance
of plaques and return of a positive PCR in skin lesions with an
ampli¢ed fragment of the same size as before treatment.
Overall, there was no signi¢cant statistical di¡erence as regards
skin or peripheral blood PCR outcome between patients clinically
responding, either partially or completely, and nonresponding to
treatment (p¼ 0.27). Conversely, a negative post-treatment PCR
in skin samples was signi¢cantly more frequent in patients
displaying both complete clinical and histologic response than
in patients with partial, dissociated or no clinical and histologic
response (p¼ 0.02) but this was not true for peripheral blood
PCR data (p¼ 0.35).
Table I. Clinical, histologic, and molecular post-treatment outcome of 27 patients with MF displaying an initial dominant
Tcell clone in skin lesions
Patients
Detection of a dominant
T cell clone in PB Clinical response Histologic response
Molecular response
in skin (and PB)
7 Ia 4/6 C: 4 C: 3 3/3 (2/2)
P: 1 0/1 (0/1)
P: 3 A: 3 0/3 (0/1)
18 Ib 10/17 C: 9 C: 9 4/9 (2/5)
P: 4 C: 1 0/1
P: 1 0/1 (1/1)
A: 2 0/2 (0/2)
A: 5 A: 5 0/5 (0/2)
2 IIa 2/2 C: 1 C: 1 1/1 (0/1)
P: 1 P: 1 0/1 (1/1)
PB, peripheral blood; C, complete; P, partial; A, absence.
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DISCUSSION
An increasing number of studies have recently demonstrated that
aTCR-targeted PCR is frequently positive in peripheral blood in
cutaneous T cell lymphomas patients including early stages of the
disease (Weiss et al, 1989; Bakels et al, 1992; Veelken et al, 1995;
Dommann et al, 1996; Curco et al, 1997; Muche et al, 1997; Fraser-
Andrews et al, 2000). Molecular data, including direct sequencing
or comparison of migration patterns of the ampli¢ed fragments
in privileged cases, favor an identity between dominant Tcell po-
pulations in skin and peripheral blood. The question of the speci-
¢city of a positive PCR in peripheral blood, however, has been
raised in other cases, all the more because a dominant gene rear-
rangement seems to be more frequently present in elderly patients
without de¢nite disease (Delfau-Larue et al, 2000). On another
hand, recent studies have clearly established that the presence of
a dominant Tcell population in peripheral blood (and possibly in
lymph nodes) was an independent unfavorable prognostic factor
in patients with MF, whether or not the same dominant popula-
tion was present in skin lesions (Bakels et al, 1992; Fraser-Andrews
et al, 2000; Andrews et al, 2001; Beylot-Barry et al, 2001;
Scarisbrick et al, 2001). The same tendency seems true when
PCR is positive in skin lesions, as a study has established that
disease stage and positive PCR in skin were both independent
elements related to a worse prognosis in patients with MF
(Delfau-Larue et al, 1998a).
Our series con¢rms that a positive PCR may be found in per-
ipheral blood in a high percentage of patients with MF as it was
present in 64% of patients. More speci¢cally, PCRwas positive
in 14 of 23 patients during the early stages (Ia and Ib) and in
two of two patients with stage IIa. The sizes of ampli¢ed se-
quences from blood and skin were identical in 13 of 16 patients
where PCRwas positive in both compartments, indirectly sug-
gesting the presence of identical T cell dominant populations in
skin and peripheral blood, perhaps originating from the same
neoplastic clone. The method we used (single-color PCR), how-
ever, was unable to identify bands that look identical in size but
may correspond to di¡erent gene rearrangements, and is unlikely
to tell apart with full accuracy PCR products that are 1 or 2 base
pairs di¡erent in size. Accordingly, a sequencing of the ampli¢ed
sequence would be required to unambiguously establish such an
identity. These data are di¡erent from the ¢gures published by
Beylot-Barry et al (2001) who found that an identical clone was
present both in skin and peripheral blood in only 25% of patients
with MF (17 of 67); however, these authors used a di¡erent meth-
od, based on GC-clamp primers and denaturing gradient gel
electrophoresis, which theoretically allows an accurate assessment
of both size and sequence of PCR products. Eventually, the higher
percentage of discordance in size between ampli¢ed fragments
obtained from skin or blood samples in more advanced clinical
stages is of questionable signi¢cance and an assessment of more
high-stage cases could help probe this question. It must be pointed
out, however, that Vega et al (2002) showed that PCR targeting
TCR-g in cutaneous T cell lymphomas patients may uncover dis-
tinct clonal gene rearrangements in di¡erent skin samples and in
skin lesions and lymph nodes; furthermore, there was a tendency
toward a more progressive disease in patients with the same gene
rearrangement in multiple concurrent biopsy specimens at the
time of diagnosis, regardless the clinical stage of the disease.
Few data are currently available regarding the outcome of
PCR data in skin and blood in patients with MF after the treat-
ment was completed. In an earlier study, Delfau-Larue et al
(1998b), usingTCR-g gene-targeted PCR followed by denaturat-
ing gradient gel electrophoresis on serial biopsies in 24 MF pa-
tients, reported that an initially positive or negative PCR was
not modi¢ed by the treatment in 89% of patients. The correla-
tions between clinical, histologic, and PCR data, however, were
not speci¢ed. Our results suggest that, although there is a rather
good relationship between clinical and histologic responses, PCR
data do not always follow the same trend as it remained positive
in skin lesions in 70% (19 of 27) of patients, including cases dis-
playing a complete clinical and histologic remission, a discre-
pancy consistent with the data from Delfau-Larue et al (1998b).
Results from peripheral blood showed a similar tendency as
PCRwas still positive after treatment in the majority (10 of 16)
of cases, including patients in complete clinical and histologic re-
mission. Taken together, our data indicate that disappearance of a
dominant gene rearrangement both in skin and blood after treat-
ment was observed in only 12.5% (two of 16) of patients and that
negative PCRwas clearly more easily obtained by therapy during
the early stages, with a better relationship with clinical and histo-
logic outcome. Indeed, all stage Ia patients with complete clinical
and histologic response displayed no evidence of dominant gene
rearrangement after the treatment was completed, whereas PCR
remained positive in skin and/or blood in a signi¢cant number of
stage Ib patients in complete clinical and histologic remission.
Overall, even if statistical analysis must be interpreted carefully
due to the limited number of patients in each subset, there seems
to be a signi¢cant correlation between complete clinical and his-
tologic response and disappearance of the skin dominant gene re-
arrangement. Accordingly, a good clinical and histologic result
could be a valuable predictor of favorable skin PCR outcome,
especially in early stage patients, but this trend needs con¢rma-
tion by large-scale studies. Conversely, the value of peripheral
blood data appears to be much more confusing with di¡erent
outcomes of the cutaneous dominant gene rearrangement and of
its blood counterpart, if present, in a number of patients; there-
fore, this study does not support the usefulness of investigating
peripheral blood PCR data in the follow-up of stage I and II
MF patients.
Eventually, no clear relationship between the type of treatment
and PCR outcome was obvious but the size of the sample was
small for each di¡erent therapeutic subset. In particular, total
body electron beam therapy, which is considered a major and
highly e¡ective therapy, did not result in the disappearance of
the dominant gene rearrangement in the three patients submitted
to this treatment, but two of them were a¡ected with more ad-
vanced disease (stage IIa). Conversely, four of 10 patients treated
with psoralenþ ultraviolet A displayed negative PCR in skin
samples after treatment was completed.
This relatively frequent persistence of a dominant gene rear-
rangement either in skin or in blood or both in patients with
MF even when the disease looks perfectly controlled by the treat-
ment is a new ¢nding but its clinical relevance is questionable.
These results might provide a valuable explanation for the fre-
quent occurrence of relapses even when a complete clinical and
histologic remission is achieved. Their signi¢cance is unclear,
however, as the true prognostic value of a positive PCR in skin
and/or peripheral blood after treatment as regards long-term out-
come of the disease would require a large-scale prospective study.
Furthermore, it is doubtful that the therapeutic aim in MF should
shift toward obtaining a negative PCR both in skin and in blood
(when positive before treatment) in all cases, as it would probably
lead to unnecessarily aggressive and toxic therapies. Such an at-
tempt to reach a molecular clearance in lesions and peripheral
blood, however, might be worthwhile in selected cases such as
late stage or multirelapsing MF when the prevention of recur-
rences may be of major interest.
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